CBIO
CRESCENT BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$12.36
+4.39%Oct 6, 2026, 20:15 UTC
Crescent Biopharma approved options to purchase an aggregate of 81,525 ordinary shares for six non-executive employees as inducement awards.
Source:Oct 5, 2026, 11:30 UTC
Crescent Biopharma received FDA clearance of its IND application for CR-002, a PD-L1-targeted topoisomerase inhibitor ADC for the treatment of solid tumors.
Source:Sep 25, 2026, 20:15 UTC
Crescent Biopharma granted options to purchase an aggregate of 31,200 ordinary shares to two non-executive employees as equity inducement awards under its 2025 Employment Inducement Incentive Award Plan.
Source:Jul 30, 2026, 00:00 UTC
Crescent Biopharma, Inc. reported its financial results for the second quarter of 2026, with zero revenue, a net loss of $24.8 million, and a diluted EPS of -0.74.
Jul 23, 2026, 20:15 UTC
Crescent Biopharma granted equity inducement awards to two new non-executive employees to secure their acceptance of employment.
Source:Jul 14, 2026, 20:01 UTC
Crescent Biopharma announced a proposed underwritten public offering of its ordinary shares and pre-funded warrants.